Antiproton radiotherapy
Нема приказа
Аутори
Bassler, NielsAlsner, Jan
Beyer, Gerd
DeMarco, John J.
Doser, Michael
Hajdukovic, Dragan
Hartley, Oliver
Iwamoto, Keisuke S.
Jaekel, Oliver
Knudsen, Helge V.
Kovacevic, Sandra
Moller, Soren Pape
Overgaard, Jens
Petersen, Jorgen B.
Sotberg, Timothy D.
Sorensen, Brita S.
Vranješ, Sanja
Wouters, Bradly G.
Hotzscheiter, Michael H.
Чланак у часопису
Метаподаци
Приказ свих података о документуАпстракт
Antiprotons are interesting as a possible future modality in radiation therapy for the following reasons: When fast antiprotons penetrate matter, protons and antiprotons have near identical stopping powers and exhibit equal radiobiology well before the Bragg-peak. But when the antiprotons come to rest at the Bragg-peak, they annihilate, releasing almost 2 GeV per anti proton-proton annihilation. Most of this energy is carried away by energetic pions, but the Bragg-peak of the antiprotons is still locally augmented with similar to 20-30 MeV per antiproton. Apart from the gain in physical dose, an increased relative biological effect also has been observed, which can be explained by the fact that some of the secondary particles from the antiproton annihilation exhibit high-LET properties. Finally, the weakly interacting energetic pions, which are leaving the target volume, may provide a real time feedback on the exact location of the annihilation peak. We have performed dosimetry experim...ents and investigated the radiobiological properties using the antiproton beam available at CERN, Geneva. Dosimetry experiments were carried out with ionization chambers, alanine pellets and radiochromic film. Radiobiological experiments were done with V79 WNRE Chinese hamster cells. The radiobiological experiments were repeated with protons and carbon ions at TRIUMF and GSI, respectively, for comparison. Several Monte Carlo particle transport codes were investigated and compared with our experimental data obtained at CERN. The code that matched our data best was used to generate a set of depth dose data at several energies, including secondary particle-energy spectra. This can be used as base data for a treatment planning software such as TRiP. Our findings from the CERN experiments indicate that the biological effect of antiprotons in the plateau region may be reduced by a factor of 4 for the same biological target dose in a spread-out Bragg-peak, when comparing with protons. The extension of TRiP to handle antiproton beams is currently in progress. This will enable us to perform planning studies, where the potential clinical consequences can be examined, and compared to those of other beam modalities such as protons, carbon ions, or IMRT photons. (C) 2007 Elsevier Ireland Ltd. All rights reserved.
Кључне речи:
antiproton / RBE / particle irradiationИзвор:
Radiotherapy and Oncology, 2008, 86, 1, 14-19
DOI: 10.1016/j.radonc.2007.11.028
ISSN: 0167-8140
PubMed: 18158194
WoS: 000253303000003
Scopus: 2-s2.0-38349091677
Колекције
Институција/група
VinčaTY - JOUR AU - Bassler, Niels AU - Alsner, Jan AU - Beyer, Gerd AU - DeMarco, John J. AU - Doser, Michael AU - Hajdukovic, Dragan AU - Hartley, Oliver AU - Iwamoto, Keisuke S. AU - Jaekel, Oliver AU - Knudsen, Helge V. AU - Kovacevic, Sandra AU - Moller, Soren Pape AU - Overgaard, Jens AU - Petersen, Jorgen B. AU - Sotberg, Timothy D. AU - Sorensen, Brita S. AU - Vranješ, Sanja AU - Wouters, Bradly G. AU - Hotzscheiter, Michael H. PY - 2008 UR - https://vinar.vin.bg.ac.rs/handle/123456789/3367 AB - Antiprotons are interesting as a possible future modality in radiation therapy for the following reasons: When fast antiprotons penetrate matter, protons and antiprotons have near identical stopping powers and exhibit equal radiobiology well before the Bragg-peak. But when the antiprotons come to rest at the Bragg-peak, they annihilate, releasing almost 2 GeV per anti proton-proton annihilation. Most of this energy is carried away by energetic pions, but the Bragg-peak of the antiprotons is still locally augmented with similar to 20-30 MeV per antiproton. Apart from the gain in physical dose, an increased relative biological effect also has been observed, which can be explained by the fact that some of the secondary particles from the antiproton annihilation exhibit high-LET properties. Finally, the weakly interacting energetic pions, which are leaving the target volume, may provide a real time feedback on the exact location of the annihilation peak. We have performed dosimetry experiments and investigated the radiobiological properties using the antiproton beam available at CERN, Geneva. Dosimetry experiments were carried out with ionization chambers, alanine pellets and radiochromic film. Radiobiological experiments were done with V79 WNRE Chinese hamster cells. The radiobiological experiments were repeated with protons and carbon ions at TRIUMF and GSI, respectively, for comparison. Several Monte Carlo particle transport codes were investigated and compared with our experimental data obtained at CERN. The code that matched our data best was used to generate a set of depth dose data at several energies, including secondary particle-energy spectra. This can be used as base data for a treatment planning software such as TRiP. Our findings from the CERN experiments indicate that the biological effect of antiprotons in the plateau region may be reduced by a factor of 4 for the same biological target dose in a spread-out Bragg-peak, when comparing with protons. The extension of TRiP to handle antiproton beams is currently in progress. This will enable us to perform planning studies, where the potential clinical consequences can be examined, and compared to those of other beam modalities such as protons, carbon ions, or IMRT photons. (C) 2007 Elsevier Ireland Ltd. All rights reserved. T2 - Radiotherapy and Oncology T1 - Antiproton radiotherapy VL - 86 IS - 1 SP - 14 EP - 19 DO - 10.1016/j.radonc.2007.11.028 ER -
@article{ author = "Bassler, Niels and Alsner, Jan and Beyer, Gerd and DeMarco, John J. and Doser, Michael and Hajdukovic, Dragan and Hartley, Oliver and Iwamoto, Keisuke S. and Jaekel, Oliver and Knudsen, Helge V. and Kovacevic, Sandra and Moller, Soren Pape and Overgaard, Jens and Petersen, Jorgen B. and Sotberg, Timothy D. and Sorensen, Brita S. and Vranješ, Sanja and Wouters, Bradly G. and Hotzscheiter, Michael H.", year = "2008", abstract = "Antiprotons are interesting as a possible future modality in radiation therapy for the following reasons: When fast antiprotons penetrate matter, protons and antiprotons have near identical stopping powers and exhibit equal radiobiology well before the Bragg-peak. But when the antiprotons come to rest at the Bragg-peak, they annihilate, releasing almost 2 GeV per anti proton-proton annihilation. Most of this energy is carried away by energetic pions, but the Bragg-peak of the antiprotons is still locally augmented with similar to 20-30 MeV per antiproton. Apart from the gain in physical dose, an increased relative biological effect also has been observed, which can be explained by the fact that some of the secondary particles from the antiproton annihilation exhibit high-LET properties. Finally, the weakly interacting energetic pions, which are leaving the target volume, may provide a real time feedback on the exact location of the annihilation peak. We have performed dosimetry experiments and investigated the radiobiological properties using the antiproton beam available at CERN, Geneva. Dosimetry experiments were carried out with ionization chambers, alanine pellets and radiochromic film. Radiobiological experiments were done with V79 WNRE Chinese hamster cells. The radiobiological experiments were repeated with protons and carbon ions at TRIUMF and GSI, respectively, for comparison. Several Monte Carlo particle transport codes were investigated and compared with our experimental data obtained at CERN. The code that matched our data best was used to generate a set of depth dose data at several energies, including secondary particle-energy spectra. This can be used as base data for a treatment planning software such as TRiP. Our findings from the CERN experiments indicate that the biological effect of antiprotons in the plateau region may be reduced by a factor of 4 for the same biological target dose in a spread-out Bragg-peak, when comparing with protons. The extension of TRiP to handle antiproton beams is currently in progress. This will enable us to perform planning studies, where the potential clinical consequences can be examined, and compared to those of other beam modalities such as protons, carbon ions, or IMRT photons. (C) 2007 Elsevier Ireland Ltd. All rights reserved.", journal = "Radiotherapy and Oncology", title = "Antiproton radiotherapy", volume = "86", number = "1", pages = "14-19", doi = "10.1016/j.radonc.2007.11.028" }
Bassler, N., Alsner, J., Beyer, G., DeMarco, J. J., Doser, M., Hajdukovic, D., Hartley, O., Iwamoto, K. S., Jaekel, O., Knudsen, H. V., Kovacevic, S., Moller, S. P., Overgaard, J., Petersen, J. B., Sotberg, T. D., Sorensen, B. S., Vranješ, S., Wouters, B. G.,& Hotzscheiter, M. H.. (2008). Antiproton radiotherapy. in Radiotherapy and Oncology, 86(1), 14-19. https://doi.org/10.1016/j.radonc.2007.11.028
Bassler N, Alsner J, Beyer G, DeMarco JJ, Doser M, Hajdukovic D, Hartley O, Iwamoto KS, Jaekel O, Knudsen HV, Kovacevic S, Moller SP, Overgaard J, Petersen JB, Sotberg TD, Sorensen BS, Vranješ S, Wouters BG, Hotzscheiter MH. Antiproton radiotherapy. in Radiotherapy and Oncology. 2008;86(1):14-19. doi:10.1016/j.radonc.2007.11.028 .
Bassler, Niels, Alsner, Jan, Beyer, Gerd, DeMarco, John J., Doser, Michael, Hajdukovic, Dragan, Hartley, Oliver, Iwamoto, Keisuke S., Jaekel, Oliver, Knudsen, Helge V., Kovacevic, Sandra, Moller, Soren Pape, Overgaard, Jens, Petersen, Jorgen B., Sotberg, Timothy D., Sorensen, Brita S., Vranješ, Sanja, Wouters, Bradly G., Hotzscheiter, Michael H., "Antiproton radiotherapy" in Radiotherapy and Oncology, 86, no. 1 (2008):14-19, https://doi.org/10.1016/j.radonc.2007.11.028 . .